Rosemary and a breakthrough blood test: The Alzheimer's research that has Bill Gates excited
Microsoft founder and US billionaire Bill Gates recently shared a post on his X handle about a new blood test for Alzheimer's that was approved by the US Food and Drug Administration (FDA) last month, along with other promising advancements in Alzheimer's research.
Gates, who has a personal and emotional connection to the disease—his father, William Gates, passed away in 2020 after a long battle with Alzheimer's—said he is genuinely excited about the progress being made in prevention, early diagnosis, and effective treatment.
Bill Gates, who wrote about the first blood test approved by FDA to diagnose Alzheimer's, said that; "...breakthroughs like this will make earlier, easier diagnosis possible—bringing us closer to better treatments and, someday, a cure."
As reported by The New Indian Express (TNIE Online) last moth the FDA approved the world's first blood test that helps detection of Alzheimer's disease in May.
Among the latest breakthroughs aimed at treatment of this yet incurable disease, another emerging name is Rosmarinus officinalis also known as Rosemary herbs -- an aromatic evergreen herb native to the Mediterranean region.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
Dose of hope
Times of India's Edit Page team comprises senior journalists with wide-ranging interests who debate and opine on the news and issues of the day. To really help, new HIV vax has to be made cheap A pill to treat multidrug-resistant HIV, lenacapavir, has been approved by US drug regulator FDA as a preventive vaccine. This is a huge deal – incidence of HIV may have declined since 1990s but even today about 13L people globally are infected by the virus every year. But its price is an obstacle. Sold for $28,218 per year in US, it's prohibitive even for high-income nations. Pharma company Gilead that manufactures lenacapavir has reportedly tied up with over 100 middle- and low-income countries for manufacture of generics pending approvals. But access likely will still be tricky for poorer African countries that bear the HIV burden. Drugs to prevent HIV transmission have been around almost a decade, but a daily dosage regimen makes these unreliable. People forget and there's the stigma/doubt in partners that a daily dose is preventive. Lenacapavir needs to be taken just twice a year. Its long-lasting effect in preventing infection – almost 100% in adults and adolescents – is thus the best bet today. Also because HIV research in US bears the additional burden of Trump administration's slashed funds. An effective vaccine for HIV has been elusive for decades because of its rapid mutations. Several mRNA vaccines, like those developed for Covid and considered the most promising, are in clinical trials. But since Jan, under Trump's health secretary Bob Kennedy Jr, NIH stopped funding hundreds of such HIV vaccine-related research. This is what makes repurposed lenacapavir a lifeline, provided it's made affordable. Facebook Twitter Linkedin Email This piece appeared as an editorial opinion in the print edition of The Times of India.
Hans India
12 hours ago
- Hans India
ZeroHarm Eyes Rs 150 Crore Milestone by FY 2025 -'26, Accelerates Global Expansion into GCC
ZeroHarm Sciences, India's pioneering clean-label nutraceutical company, is set to accelerate its global footprint with a focused expansion into the GCC markets, including the UAE and the broader Middle East. Following a remarkable 10× revenue growth over the past two years and operating at a healthy ~20% EBITDA margin, the company closed the last fiscal year with 71 crore in gross revenue with an exit ARR of 90 crores. In the current fiscal, ZeroHarm is aiming for ₹150 crore in gross revenue, driven by strong domestic and global momentum and increasing traction in the United States, which now contributes nearly 30% of its overall revenue. At the heart of ZeroHarm's global success is its patented ZeroHarm BioEnhance platform, a pharma-grade nanotechnology that encapsulates plant-based actives at the nanoscale, dramatically enhancing their bioavailability by up to 5×, ensuring faster onset, precise dosing, and residue-free delivery. This breakthrough, backed by granted patents and deep R&D, makes ZeroHarm the first Indian company to bring pharmaceutical nanotech into nutraceuticals at scale. ZeroHarm's US FDA, CE, and ISO-certified formulations are backed by government-led clinical trials, with documented claims for 15 products, setting it apart in a market rife with unverified health claims. Today, the company offers over 70 targeted, condition-specific products spanning diabetes, arthritis, PCOS, liver and kidney health, immunity, and oncology support, with over million units sold across India to date. Backed by a fully owned, nanotech-enabled manufacturing facility, ZeroHarm can produce up to ₹250 crore worth of finished goods annually, making it one of the few Indian nutraceutical brands with true end-to-end production capabilities. To support its international expansion, ZeroHarm has acquired a dedicated manufacturing and R&D facility in the United States, enhancing local supply chain efficiency, fast-tracking formulation innovation, and enabling closer clinical and regulatory collaborations in key global markets. The U.S. infrastructure also gives ZeroHarm a significant strategic edge in developed markets, where stringent compliance standards often limit entry for Indian nutraceutical brands reliant on contract manufacturing. 'The global nutraceutical market is shifting, consumers are demanding not just clean labels, but clinical credibility. At ZeroHarm, we've combined deep R&D with pharma-grade nanotechnology to raise the bar for efficacy, safety, and transparency in preventive wellness. Our entry into the GCC is a natural extension of the trust we've built in India and the U.S., and a significant step toward making evidence-backed, plant-based therapeutics accessible to global consumers,' said Sachin Darbarwar, Founder & CEO, ZeroHarm Sciences. With distribution agreements and regulatory filings already underway, the company will also launch in the UK aside from the GCC markets by Q3 2025, introducing its clinically tested product lines via pharmacies, e-commerce platforms, and integrative practitioner networks.
Hindustan Times
16 hours ago
- Hindustan Times
Artichokes, a beloved Mediterranean vegetable, are a true culinary gem
Artichokes, a beloved Mediterranean vegetable, are a true culinary gem. With tender hearts and meaty leaves, they offer a subtle, nutty flavour perfect for antipasti, dips, pasta, and gourmet salads. A staple in Italian, French, and Spanish cuisine, artichokes can be grilled, stuffed, steamed, or marinated — adding elegance and depth to even Indian dishes. Preparing and eating them may take effort, but it's a labour of love your taste buds will thank you for. Once you remove the leaves and the choke, you'll reach the prized heart — a delicious reward for your patience. Cutting artichokes can seem tricky at first, but with a little practice, it becomes much easier. Medicos and dieticians alike praise artichokes for their abundance of antioxidants, fiber, and essential nutrients. They are known to support digestive health, liver function, and heart wellness. Dr Poonam Tiwari, Head of the Department of Dietetics at RMLIMS, highlights, 'Artichoke helps to regulate cholesterol levels and, as it contains cynarine, it supports bile production. It's low in calories and high in vitamins. Artichokes are both a nutritious and delicious addition to a healthy diet. Don't overcook or fry it to retain its authentic flavours.' Due to their preference for a Mediterranean climate, artichokes aren't widely cultivated in India. However, they are occasionally grown on a small scale in cooler regions like parts of Himachal Pradesh and Uttarakhand. They can be spotted in gourmet stores, with prices reaching up to ₹4,000 per piece. Despite their limited availability, the increasing interest in global cuisines is paving the way for artichokes to become a more common sight on Indian tables. Mediterranean Artichoke & Quinoa Salad Chef Mohd Shavez Ahmad, faculty at IHM, shares his recipe for a popular salad: 'Combine cooked quinoa with chopped canned artichoke hearts, cherry tomatoes, cucumber, Kalamata olives, and fresh parsley. Toss with a light dressing made of olive oil, lemon juice, garlic, and a pinch of salt and pepper. This salad is packed with protein, fiber, and antioxidants, making it perfect for a nourishing, cool meal during hot days. It's easy to prepare and offers a delightful balance of flavours and textures.' For a refreshing summer option, Chef Shavez offers an easy raita recipe: 'Try a Chilled Artichoke & Cucumber Raita — a refreshing twist on a classic Indian side. Made using readily available canned or marinated artichoke hearts (found in gourmet stores or online), chopped cucumber, hung curd, mint, and a dash of roasted cumin powder, it's light, cooling, and perfect for hot summers. This fusion raita pairs beautifully with grilled dishes or can be enjoyed on its own as a healthy snack, blending global taste with local ease.' Artichoke & Watermelon Chaat Ranjan Thakur, Executive Chef at Fairfield Marriott, suggests a gourmet twist for summer snacking with Artichoke and Watermelon Chaat: 'Combine juicy watermelon cubes with chopped canned artichoke hearts, a sprinkle of chaat masala, lemon juice, black salt, and fresh mint. This fusion salad offers the familiar tang of Indian street-style chaat with the delicate, nutty flavour of artichokes — perfect for warm climate. It's quick to prepare, hydrating, and ideal for those looking for something tasty yet healthy and unique.'
